Overview

An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Status:
Completed
Trial end date:
2014-11-30
Target enrollment:
Participant gender:
Summary
This observational trial will examine the efficacy and safety of Mircera for renal anemia in participants with stage III-IV CKD in daily clinical practice. Mircera will be prescribed by treating physician and followed for approximately 36 months.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Epoetin Alfa